TEMPUS   Report issue

For profit Phase 2 Phase 4
Founded: Chicago IL United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2015
NCT00241618
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Tempus Labs | Tempus Labs, Inc.

Active Ingredients

Drugs in Phase 4 Trials (2)

interferon alpha-2b (Intron-A) (2 trials)

ribavirin (virazole) (2 trials)

Drugs in Phase 2 Trials (3)

a2b530 (1 trial)

a2b694 (1 trial)

niraparib (zejula) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 5